Download - Bayer HealthCare

More documents

Recommendations

Info

Fostering real partnerships which offer both sides the opportunity to develop and grow – that is the partnering philosophy of Bayer HealthCare. Business development
As an innovation- and growth-oriented company, Bayer HealthCare also invests in setting up and maintaining collaborations with external partners. These partnerships cover a broad variety of models ranging from r&D collaborations, licensing and co- marketing agreements to regional alliances and acquisitions. Strategic alliances with international partners from academia are an important pillar of the company’s R&D strategy. Examples are the joint research center for innovative therapeutic approaches at Tsinghua University (China) and the collaboration with the German Cancer Research Center (Heidelberg). Other collaborations at earlier stage include the multi-target drug discovery alliance with Evotec AG from Germany in the area of endometriosis. With the targeted anticancer drug Nexavar (sorafenib), the Pharmaceuticals Division and Onyx Pharmaceuticals, Inc., USA, have gone all the way from drug discovery to market. Another example in the area of Oncology is the successful co-development of radium-223 dichloride with Algeta ASA from norway. Bayer HealthCare just recently submitted this substance for marketing authorization in the EU and the United States for the treatment of castration-resistant prostate cancer patients with bone metastases. In collaboration with Regeneron Pharmaceuticals, Inc., Eylea (aflibercept) has been successfully launched for the treatment of wet age-related macular degenera- tion and central retinal vein occlusion. Another example of a fruitful partnership is the co-development and co-promotion agreement with Janssen Pharmaceuticals for the anticoagulant Xarelto (rivaroxaban). This collaboration has led to launches in multiple locations worldwide. Bayer HealthCare Animal Health recently acquired the U.S. animal health business of Teva Pharmaceutical Industries. This transaction reinforces Bayer’s product offering in the USA with anti-infectives for livestock and adds reproductive hormones to the existing portfolio. The acquisition also strengthens the company’s companion animal franchise with the addition of dermatological, pet wellness and nutraceutical products. The Consumer Care Division continues to focus its business development efforts to strengthen its position in the United States and to accelerate growth in emerging markets including Brazil, China and Russia. In addition, the division will expand its portfolio into adjacent business categories, as well as Rx to OTC switch opportunities. BuSinESS DEvEloPMEnT 23
Page 1 and 2: Bayer HealthCare A Company Overview
Page 3 and 4: innovations in health care Bayer He
Page 5 and 6: or farm animals for food production
Page 7 and 8: The goals of the Animal Health Divi
Page 9 and 10: A growing number of individuals wor
Page 11 and 12: Bayer HealthCare’s Medical Care D
Page 13 and 14: Bayer HealthCare’s success story
Page 15 and 16: Continued from page 13 of the uteru
Page 17 and 18: €1,962 million of the Bayer Group
Page 19 and 20: expertise. The current R&D focus in
Page 21: Bayer HealthCare manufactures produ
Page 25 and 26: in the 21st century, the world will
Page 27 and 28: Bayer HealthCare names - Figures -
Page 29 and 30: Germany United States China Japan M

Download - Bayer HealthCare

Create successful ePaper yourself

Delete template?

Save as template?